In this issue of Clinical Autonomic Research, Bhandari and colleagues publish a comprehensive state-of-the-art review on cyclic vomiting syndrome [1] . As described in this article, cyclic vomiting syndrome is a difficult, presumably neural as well as psychological condition. The neural etiology appears to be the underlying pathophysiology in cannabis users, whereas the psychological background is more evident in non-cannabis users.
Vomiting is a relatively common occurrence in the adult and pediatric populations, with up to 6% of pediatric patients complaining of functional nausea and vomiting [2] . When these patients present to clinic, practitioners typically perform a work-up to rule out systemic disorders by blood tests, upper endoscopy, abdominal imaging, or other diagnostic modalities focused on the gastrointestinal tract itself. What most general practitioners and gastroenterologists perhaps forget is that the gastrointestinal tract is intimately controlled by the central and peripheral nervous systems. Indeed, the autonomic nervous system is involved in the initiation and expression of emesis, in response to a number of stimuli, including endogenous cannabinoids binding to cannabinoid receptors located in central and peripheral pathways [3] (Fig. 1) .
The link between the endocannabinoid system and the autonomic nervous system is increasingly documented. A recently published article in Clinical Autonomic Research reviewed the endocannabinoid mechanisms involved in autonomic cardiovascular control [8] . In this regard, several gastrointestinal disorders featuring prominent nausea and vomiting, such as cyclic vomiting syndrome, are associated with clinical manifestations of autonomic dysfunction and objective abnormalities on autonomic function testing. Conversely, autonomic dysfunction caused by neurodegeneration (such as Parkinson disease and other synucleinopathies), genetic mutations (e.g., familial dysautonomia), or focal brain lesions in the dorsal vagal complex (Fig. 1 ) [7] can present with disabling nausea and vomiting. In the case of familial dysautonomia, the mechanism of nausea is related to massive dopamine release [5] . Of note, in patients with Parkinson disease treatment with L-dopa also triggers nausea, which can be relieved by blocking the peripheral conversion of L-dopa to dopamine with carbidopa, a dopadecarboxylase inhibitor. This is why L-dopa is commercialized in combination with carbidopa [4] . Carbidopa (without L-dopa) also relieves hyperdopaminergic-vomiting crisis in patients with familial dysautonomia [6] . Whether dopamine pathways are also involved in cyclic vomiting syndrome is unknown, but the hypothesis is tempting.
In the meantime, as described by Bhandari and colleagues [1] , available therapies acting on dopaminergic and serotoninergic receptors in the nervous system are effective at attenuating nausea and vomiting. This is also the case with the most extensively studied etiology of severe emesis, i.e., chemotherapy-induced nausea and vomiting, which is also preventable and treatable by agents targeting neurokinin, dopamine, serotonin, and endocannabinoid receptors located in the peripheral and central nervous systems. These few examples provide insights of potentially effective therapies for patients with cyclic vomiting syndrome and highlight how, in the case of vomiting nausea, the nervous system has the guts.
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